Phase 4RecruitingNCT03878459
Dapagliflozin plus pioglitazone in T1D
Adjunct metabolic trial combining SGLT2 inhibition with pioglitazone in type 1 diabetes, relevant to glycemia/ketoacidosis trade-offs.
Primary endpoints
- Decrease in HbA1c
Results so far
No results posted yet.